HCM

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.41
Percentage change -2.52	%

Peers: JNJ BGNE ZLAB ASND IMAB MGNX JSPR WWW ADAG HUYA

| Held by: SPDW CNCR BIB IBBQ NSI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.25	Insider Own	2.30%	Shs Outstand	174.31M	Perf Week	-5.54%
Market Cap	2.77B	Forward P/E	133.36	EPS next Y	0.12	Insider Trans	0.00%	Shs Float	170.31M	Perf Month	-9.21%
Income	-43.43M	PEG	-	EPS next Q	-0.04	Inst Own	4.23%	Short Float	0.30%	Perf Quarter	-8.21%
Sales	617.39M	P/S	4.48	EPS this Y	-120.77%	Inst Trans	-24.79%	Short Ratio	5.49	Perf Half Y	-14.86%
Book/sh	4.25	P/B	3.74	EPS next Y	195.51%	ROA	-3.40%	Short Interest	0.51M	Perf Year	-17.69%
Cash/sh	4.60	P/C	3.45	EPS next 5Y	44.50%	ROE	-5.71%	52W Range	11.93 - 21.92	Perf YTD	-12.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5.46%	52W High	-27.60%	Beta	0.78
Dividend TTM	-	Quick Ratio	2.68	Sales past 5Y	35.89%	Gross Margin	41.68%	52W Low	32.98%	ATR (14)	0.72
Dividend Ex-Date	-	Current Ratio	2.81	EPS Y/Y TTM	-28.50%	Oper. Margin	-19.89%	RSI (14)	36.55	Volatility	2.99% 2.55%
Employees	1988	Debt/Eq	0.11	Sales Y/Y TTM	-19.35%	Profit Margin	-7.03%	Recom	1.17	Target Price	30.69
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-79.15%	Payout	0.00%	Rel Volume	1.79	Prev Close	16.28
Sales Surprise	-4.27%	EPS Surprise	138.22%	Sales Q/Q	53.61%	Earnings	Jul 31 AMC	Avg Volume	92.75K	Price	15.87
SMA20	-7.32%	SMA50	-14.47%	SMA200	-12.52%	Trades		Volume	165,997	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-23	Upgrade	Deutsche Bank	Hold → Buy
May-04-22	Downgrade	Deutsche Bank	Buy → Hold
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$46
Aug-03-21	Initiated	Jefferies	Buy	$52
Oct-02-20	Initiated	Deutsche Bank	Buy	$40
Mar-13-20	Initiated	Cantor Fitzgerald	Overweight
Feb-20-20	Initiated	Goldman	Buy
Nov-19-19	Initiated	CLSA	Buy
Oct-23-19	Reiterated	BofA/Merrill	Buy	$35 → $29
Jul-05-19	Initiated	Macquarie	Outperform

Dec-11-24 11:00PM	HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy (GlobeNewswire)
Dec-03-24 07:00PM	Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT (Sintilimab Injection) in Combination with ELUNATE (Fruquintinib) for the Treatment of Advanced Endometrial Cancer (PR Newswire)
05:00AM	HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer (GlobeNewswire)
Nov-28-24 05:30AM	HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at Current Terms (GlobeNewswire)
Nov-21-24 11:30PM	HUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan (GlobeNewswire)
04:30AM	Loading…
Nov-20-24 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee (GlobeNewswire) +7.22%
Nov-05-24 11:00PM	HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress (GlobeNewswire)
Oct-31-24 04:30AM	HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda (GlobeNewswire) -5.01%
Oct-16-24 12:30AM	HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial (GlobeNewswire) +5.32%
Oct-09-24 03:30PM	HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... (GuruFocus.com)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +5.31%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) +5.32%
Sep-24-24 03:00AM	HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire) +5.15%
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
08:00PM	Loading…
Sep-08-24 08:00PM	HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer (GlobeNewswire)
Aug-30-24 12:30AM	HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China (GlobeNewswire)
Aug-28-24 12:24PM	HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-21-24 04:30AM	HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia (GlobeNewswire)
Jul-31-24 07:00AM	HUTCHMED Reports 2024 Interim Results and Provides Business Updates (GlobeNewswire) +8.00%
Jul-03-24 08:00PM	HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status (GlobeNewswire) +5.37%
Jun-26-24 04:30AM	HUTCHMED to Announce 2024 Half-Year Financial Results (GlobeNewswire)
Jun-24-24 05:30AM	Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 (GlobeNewswire)
Jun-21-24 04:00PM	HUTCHMED Announces European Commission Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire)
Jun-16-24 08:00PM	HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology (GlobeNewswire)
Jun-06-24 08:00PM	HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China (GlobeNewswire)
Jun-02-24 08:00PM	HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine (GlobeNewswire)
May-23-24 08:00PM	HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-17-24 10:00AM	HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees (GlobeNewswire)
May-16-24 08:00PM	HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress (GlobeNewswire)
08:00PM	Loading…
May-13-24 08:00PM	HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China (GlobeNewswire)
08:00PM	HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui (GlobeNewswire)
08:00PM	HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui (GlobeNewswire)
May-08-24 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee (GlobeNewswire)
Apr-30-24 12:00PM	HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? (Zacks)
Apr-26-24 08:30AM	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda (GlobeNewswire)
Apr-05-24 04:30AM	HUTCHMED Highlights Data to be Presented at AACR Congress 2024 (GlobeNewswire)
Apr-02-24 12:30AM	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status (GlobeNewswire)
Mar-27-24 08:00PM	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC (GlobeNewswire)
08:00PM	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC (GlobeNewswire)
Mar-21-24 08:00PM	HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China (GlobeNewswire) -5.10%
Feb-28-24 06:30AM	HUTCHMED Reports 2023 Full Year Results and Provides Business Updates (GlobeNewswire)
Feb-06-24 07:00PM	HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session (GlobeNewswire) +11.84%
Feb-02-24 03:30AM	HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership (GlobeNewswire)
Feb-01-24 03:30AM	HUTCHMED to Announce 2023 Final Results (GlobeNewswire)
Jan-29-24 11:53PM	HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer (GlobeNewswire)
Jan-10-24 07:00PM	HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status (GlobeNewswire)
Dec-12-23 11:30PM	HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms (GlobeNewswire)
07:00PM	HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China (GlobeNewswire)
Nov-30-23 07:00PM	HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses (GlobeNewswire)
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) +5.14%
Nov-08-23 07:11PM	HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer (GlobeNewswire) -7.23%
Nov-01-23 08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts (GlobeNewswire)
Oct-31-23 08:35PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 (GlobeNewswire)
Oct-16-23 04:30AM	HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 (GlobeNewswire)
Oct-10-23 12:08PM	Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics (GuruFocus.com)
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey)
Sep-29-23 04:30AM	HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan (GlobeNewswire)
Sep-25-23 12:20PM	Is HUTCHMED (China) Ltd (HCM) Set to Underperform? Analyzing the Factors Limiting Growth (GuruFocus.com) +6.44%
Sep-18-23 12:14PM	Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics (GuruFocus.com) +8.63%
Sep-12-23 04:30AM	HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer (GlobeNewswire)
Sep-11-23 08:00PM	HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China (GlobeNewswire) +6.63%
12:14PM	Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics (GuruFocus.com)
Aug-28-23 08:00PM	HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer (GlobeNewswire) +7.16%
Aug-20-23 08:00PM	HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China (GlobeNewswire)
Aug-03-23 01:07AM	HUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022) (Simply Wall St.) +11.57%
Jul-31-23 07:41AM	HUTCHMED Reports 2023 Interim Results and Provides Business Updates (GlobeNewswire)
Jul-19-23 08:00PM	HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study (GlobeNewswire)
Jul-13-23 04:30AM	HUTCHMED Announces Changes to Board of Directors and Technical Committee (GlobeNewswire)
Jul-09-23 08:00PM	HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China (GlobeNewswire)
Jun-26-23 04:30AM	HUTCHMED to Announce 2023 Half-Year Financial Results (GlobeNewswire)
Jun-15-23 08:30PM	HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet (GlobeNewswire) +8.20% +5.38%
10:30AM	Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency (GlobeNewswire)
Jun-09-23 05:30AM	HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings (GlobeNewswire)
May-25-23 07:00PM	Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review (GlobeNewswire) +9.66%
06:00PM	HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-18-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) -5.63%
May-15-23 08:15AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 (GlobeNewswire) +5.79%
May-12-23 04:30AM	HUTCHMED Announces Board of Directors and Board Committee Membership (GlobeNewswire)
May-11-23 05:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 (GlobeNewswire)
May-10-23 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees (GlobeNewswire)
May-09-23 01:36PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 (GlobeNewswire) -9.34%
Apr-17-23 08:00PM	HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer (GlobeNewswire) -5.25%
Apr-11-23 08:00PM	HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.87%
04:30AM	Intended Retirement of Independent Non-executive Director (GlobeNewswire)
Apr-04-23 05:30AM	HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations (GlobeNewswire) +6.26%
Mar-30-23 08:00PM	HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer (GlobeNewswire)
Mar-14-23 09:30AM	HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China (GlobeNewswire) +7.26%
Mar-12-23 08:07PM	HUTCHMED Confirms No Assets Held at Silicon Valley Bank (GlobeNewswire)
Feb-28-23 03:30AM	HUTCHMED Reports 2022 Full Year Results and Provides Business Updates (GlobeNewswire) +5.35%
Feb-27-23 05:00AM	HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China (GlobeNewswire)
Jan-31-23 03:30AM	HUTCHMED to Announce 2022 Final Results (GlobeNewswire)
Jan-23-23 08:00AM	HUTCHMED Out Licenses Fruquintinib To Takeda Outside China (Benzinga) +5.95%
03:00AM	HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China (GlobeNewswire)
Jan-18-23 09:30AM	HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China (GlobeNewswire)
Jan-03-23 03:30AM	HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China (GlobeNewswire) +10.83%
Dec-19-22 05:00AM	HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer (GlobeNewswire)
Dec-16-22 06:27AM	Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology (GlobeNewswire)
Nov-18-22 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire)

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUTCHMED (China) Limited ADR

Upgrade your FINVIZ experience